Shares of Prana Biotechnology Limited (NASDAQ:PRAN) have been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Analysts have set a twelve-month consensus price objective of $4.00 for the company, according to Zacks. Zacks has also assigned Prana Biotechnology an industry rank of 101 out of 255 based on the ratings given to its competitors.
Several equities analysts recently commented on PRAN shares. Zacks Investment Research upgraded shares of Prana Biotechnology from a “sell” rating to a “hold” rating in a research note on Wednesday, May 23rd. ValuEngine upgraded shares of Prana Biotechnology from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.
Prana Biotechnology traded up $0.09, hitting $2.17, during trading hours on Friday, Marketbeat.com reports. 10,342 shares of the company traded hands, compared to its average volume of 13,392. Prana Biotechnology has a twelve month low of $1.75 and a twelve month high of $3.79.
Prana Biotechnology Company Profile
Prana Biotechnology Limited develops therapies for the treatment of Alzheimer's disease, Huntington disease, and other neurodegenerative disorders in Australia. Its lead drug candidates include PBT2, which is in Phase IIb clinical trials for the treatment of Alzheimer's: and that is in Phase IIa clinical trials for the treatment of Huntington's diseases.
Further Reading: How to Invest in Marijuana Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.